Close

Inovio Pharma (INO) Says it Achieved Third Cancer Indication Milestone for MEDI0457 Phase 2 Development

April 8, 2019 9:01 AM EDT Send to a Friend
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it achieved a third indication milestone from AstraZeneca resulting from dosing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login